Autolus Therapeutics plc filed a voluntary quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the three and nine months ended September 30, 2026, disclosing financial results and operational updates for the period.
Key Highlights
- Voluntary filing: Autolus, qualifying as a Foreign Private Issuer, voluntarily elected to file this quarterly report rather than being required to do so under U.S. exchange rules.
- Share count: As of November 9, 2026, the company had 266,340,330 ordinary shares outstanding, including shares in the form of American Depositary Shares.
- Listed security: American Depositary Shares trade on NASDAQ:AUTL, with each ADS representing one ordinary share at par value $0.000042 per share.
- Commercial product: AUCATZYL (obecabtagene autoleucel, or obe-cel) is the company's approved CAR-T cell therapy indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
- Regulatory approvals: According to the filing, AUCATZYL holds regulatory approval in the United States, European Union, and United Kingdom.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company under SEC definitions.
Autolus Quarterly Disclosure: AUCATZYL Commercialization and Financial Period
Autolus Therapeutics plc, incorporated in England and Wales and headquartered at The Mediaworks, 191 Wood Lane, London, W12 7FP, filed this quarterly report covering the period ended September 30, 2026. The company noted in the filing that, as a Foreign Private Issuer under Rule 3b-4 of the Securities Exchange Act of 1934, it is ordinarily exempt from the obligation to file quarterly reports on Form 10-Q. It has nonetheless "voluntarily elected to file this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026."
The filing centers on AUCATZYL, the company's marketed CAR-T therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). According to the filing, the company's ability to generate revenues from AUCATZYL "is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors." The company disclosed plans to expand commercialization into additional territories beyond the United States, European Union, and United Kingdom, where it currently holds regulatory approval.
The filing's financial statements cover condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025, and condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025. The document also notes that AUCATZYL is a registered trademark of the company. As a Foreign Private Issuer, Autolus stated it remains exempt from U.S. federal proxy rules under Section 14 of the Exchange Act, Regulation FD, and Section 16 short-swing profit provisions.
What Was Disclosed
Autolus Therapeutics plc submitted a voluntary quarterly report for the period ended September 30, 2026, covering financial results, the commercial status of AUCATZYL for adult r/r B-ALL, and its standing as a Foreign Private Issuer with 266,340,330 ordinary shares outstanding as of November 9, 2026.



Please wait processing your request...